薄层黑色素瘤前哨淋巴结活检预测因素:AJCC第8版分期系统的影响
该研究利用2021年美国国家癌症数据库黑色素瘤数据,分析2012至2021年薄层黑色素瘤(厚度≤1.0 mm)前哨淋巴结活检(SLNB)的使用率和阳性率在AJCC第7版与第8版分期时代的差异。结果显示SLNB总体使用率约30%保持稳定,但第8版时代SLNB阳性率从4.5%升至6.6%(p<0.001),且T1b(0.8-1.0 mm)SLNB使用增加(OR 2.53,95%CI 2.31-2.78),T1a(<0.8 mm)使用减少(OR 0.80,95%CI 0.76-0.85)。
要点
- AJCC第8版实施后,薄层黑色素瘤SLNB阳性率从4.5%升至6.6%。
- T1b(0.8-1.0 mm)SLNB使用增加(OR 2.53,95%CI 2.31-2.78)。
- T1a(<0.8 mm)SLNB使用减少(OR 0.80,95%CI 0.76-0.85)。
核心结论
- AJCC第8版分期实施后,外科医生对薄层黑色素瘤SLNB选择更谨慎,SLNB阳性率相应升高。
研究设计与样本
- 回顾性队列研究,使用2021年美国国家癌症数据库黑色素瘤参与用户文件,纳入2012至2021年厚度≤1.0 mm的薄层黑色素瘤病例共136,966例,其中76,485例(55.8%)诊断于AJCC第7版时代(2012-2017)。
主要发现
- 薄层黑色素瘤接受SLNB的总体比例在比较时段内相对稳定,约30%。
- AJCC第8版时代总体SLNB阳性率从4.5%升至6.6%(p<0.001)。
- 厚度0.8-1.0 mm(T1b) melanoma的SLNB使用增加(OR 2.53,95%CI 2.31-2.78),厚度<0.8 mm(T1a)使用减少(OR 0.80,95%CI 0.76-0.85)。
- 两个厚度组的SLNB阳性率随时间均升高。
临床怎么用
- 临床实践中对薄层黑色素瘤应依据AJCC第8版分期分层选择SLNB,T1b(0.8-1.0 mm)可考虑SLNB,T1a(<0.8 mm)需更选择性使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The definition of T1b cutaneous melanoma was changed in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system based on survival differences but not risk of sentinel lymph node (SLN) metastases. We sought to evaluate changes in SLNB use and rates of positive SLNB in response to updated staging criteria, and to evaluate the incidence of high-risk features in T1a melanoma in whom SLNB is now recommended. STUDY DESIGN: The 2021 National Cancer Database Melanoma Participant User File was used to obtain SLNB use and positivity rates in T1 (thin) melanoma (thickness 1.0 mm or less) from 2012 to 2021. Rates were compared between AJCC 7th (2012 to 2017) and 8th editions (2018 to 2021). Factors associated with SLNB use in nonulcerated T1 melanoma were evaluated. The presence of high-risk features in T1a melanoma was identified and SLN positivity rates were reviewed. RESULTS: A total of 136,966 cases were included with 76,485 (55.8%) cases diagnosed under the AJCC 7th edition era (2021 to 2017). The overall proportion of patients with thin melanoma undergoing SLNB was relatively stable over the time periods, roughly 30%. In the AJCC 8th edition era, the overall SLNB positivity rate slightly increased from 4.5% to 6.6% (p < 0.001). There was increased SLNB use in melanoma with a thickness of 0.8 to 1.0 mm (T1b: odds ratio 2.53 [95% CI 2.31 to 2.78]) and decreased use when the thickness was less than 0.8 mm (T1a: odds ratio 0.80 [0.76 to 0.85]). The rate of SLNB positivity increased in both thickness groups over time. CONCLUSIONS: After implementation of the AJCC 8th edition staging criteria, surgeons have become more selective in SLNB use with a resulting increase in SLNB positivity rate. Fewer SLNBs in T1a and more SLNBs in nonulcerated T1b are being performed.
引用
- Donica WR, Stephens KR, Philips P, et al. Predictors of SLNB in Thin Melanoma: Understanding the Impact of the American Joint Committee on Cancer 8th Edition Staging System. J Am Coll Surg. 2025. PMID: 39846473. doi:10.1097/XCS.0000000000001296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。